Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection
Tóm tắt
This study was performed to assess oral valganciclovir V-GCV (GCV pro-drug), 15 mg/kg bid for 6 weeks to 13 neonates with symptomatic congenital cytomegalovirus (CMV). We monitored plasma levels of GCV within 30 days of therapy: Ctrough, and C2h (before and the 2 hours after administration), we performed viral assessment in plasma and urine and tolerability at baseline, and every fortnight. Pharmacokinetics showed GCV stable and effective plasma concentrations: mean Ctrough = 0.51 ± 0.3 and C2h : 3.81 ± 1.37 μg/ml. No significant variability was seen neither intra-patient nor inter-patients. One newborn discontinued therapy because of thrombocytopenia, another finished with a neutrophils count of 1,000/μl. At the end of therapy 6 out of 12 and 8 out of 12 newborns were negative for CMV in urine and plasma. The 4 newborns positive for CMV DNA showed a 90% reduction of pre-therapy values. Clinically, the 4 patients reporting hepatic disease and the 3 with thrombocytopenia recovered after 6 weeks of therapy. Eight newborns suffered from SNHL; at the 6-month follow-up no patients had worsened, 2 had improved, and no deterioration was reported in 3 newborns with chorioretinitis scarring. The paucity of adverse events, and the effectiveness and stability of drug plasma concentrations are the important findings of our study.
Tài liệu tham khảo
Dollard SC, Grosse SD, Ross DS (2007) New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17:355–363
Michaels MG (2007) Treatment of congenital cytomegalovirus: where are we now? Expert Rev Anti Infect Ther 5:441–448
Schleiss MR (2008) Congenital cytomegalovirus infection: update on management strategies. Curr Treat Options Neurol 10:186–192
Adler SP, Nigro G, Pereira L (2007) Recent advances in the prevention and treatment of congenital cytomegalovirus infections. Semin Perinatol 31:10–18
Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253–276
Kimberlin DW, Lin CY, Sanchez P et al (2003) Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomised, controlled trial. J Pediatr 143:16–25
Boppana SB, Fowler KB, Pass RF et al (2005) Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. J Pediatr 146:817–823
Gerna G, Baldanti F, Percivalle E et al (2003) Early identification of human cytomegalovirus strains by the shell vial assay is prevented by a novel amino acid substitution in UL123 IE1 gene product. J Clin Microbiol 41:4494–4495
Revello MG, Campanini G, Piralla A et al (2008) Molecular epidemiology of primary human cytomegalovirus infection in pregnant women and their family. J Med Virol 80:1415–1425
Lombardi G, Di Comite A, Decembrino L et al (2007) Valganciclovir treatment of newborns with symptomatic congenital cytomegalovirus (CMV) infection. 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, 9–14 September, Nice, France
Burri M, Wiltshire H, Kahlert C et al (2004) Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl. Pediatr Infect Dis J 23:263–266
Chu F, Kiang CH, Sung ML et al (1999) A rapid, sensitive HPLC method for the determination of canciclovir in human plasma and serum. J Pharm Biomed Anal 21:657–667
Anaizi NH, Dentinger PJ, Swenson CF (2002) Stability of valganciclovir in extemporaneously compounded oral liquid. Am J Health Syst Pharm 59:1267–1270
Henkin CC, Grenor JC, Ten Eick AP (2003) Stability of valganciclovir in extemporaneously compounded liquid formulations. Am J Health Syst Pharm 60:687–690
Curran M, Noble S (2001) Valganciclovir. Drugs 61:1145–1150
Schulzke S, Buhrer C (2006) Valganciclovir for treatment of congenital cytomegalovirus infections. Eur J Pediatr 165:575–576
Jansen CFM, Toet MC, Rademaker CMA et al (2005) Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir. J Perinat Med 33:364–366
Galli L, Novelli A, Chiappini E et al (2007) Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants. Pediatr Infect Dis J 26:451–453
Kimberlin DW, Acosta EP, Sanchez PJ et al (2008) Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 197:836–845
Acosta EP, Brundage RC, King JR et al (2007) Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of liquid valganciclovir formulation. Clin Pharmacol Ther 81:867–872
Lanari M, Lazzarotto T, Venturi V et al (2006) Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. Pediatrics 117:76–81
Bradford RD, Cloud G, Lakeman AD et al (2005) Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. J Infect Dis 191:227–233
Rivera LB, Boppana SB, Fowler KB et al (2002) Predictor of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics 110:762–767
Jones CA, Walker KS, Henderson-Smart DJ (2005) Antiviral therapy for symptomatic congenital cytomegalovirus infection in neonates and infants up to 3 months of age. The Cochrane Library Issue 1. Cochrane Collaboration, Wiley, New York, pp 1–6
Nassetta L, Kimberlin D, Whitley R (2009) Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J Antimicrob Chemother 63:862–867
Muller A, Eis-Hubinger AM, Brandhorst G et al (2008) Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant. J Perinatol 28:74–76